Endo International PLC
LSE:0Y5F
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Endo International PLC
Operating Income
Endo International PLC
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Endo International PLC
LSE:0Y5F
|
Operating Income
$259.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Operating Income
$312.8m
|
CAGR 3-Years
23%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-8%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Operating Income
$517.6m
|
CAGR 3-Years
68%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Operating Income
-$5m
|
CAGR 3-Years
63%
|
CAGR 5-Years
31%
|
CAGR 10-Years
19%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Operating Income
-$60.7m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-167%
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Operating Income
-€3.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
Endo International PLC
Glance View
Endo International PLC is a specialty pharmaceutical company that operates at the intersection of innovation and necessity within the healthcare industry. Its primary business involves developing, manufacturing, and marketing both branded and generic pharmaceutical products. Endo thrives on a diversified portfolio that spans numerous therapeutic areas, including pain management, urology, orthopedics, and endocrinology. The company strategically positions itself by addressing unmet medical needs, often targeting niche markets where the competition is minimal, thus allowing for premium pricing and robust profit margins. Endo's revenue streams are driven by a blend of proprietary and generic drugs, with a significant portion coming from its well-known brands such as PERCOCET® and SUPPRELIN® LA. Its generics division supplements this by producing cost-effective versions of popular drugs, supporting market accessibility and appealing to cost-sensitive consumers and healthcare providers. By leveraging its research and development capabilities, Endo continues to enhance its product portfolio and explore new market opportunities. The company's growth is rooted in its ability to adapt to the ever-changing regulatory landscape, optimize its operations for efficiency, and forge strategic partnerships that enhance its market reach.
See Also
What is Endo International PLC's Operating Income?
Operating Income
259.8m
USD
Based on the financial report for Dec 31, 2022, Endo International PLC's Operating Income amounts to 259.8m USD.
What is Endo International PLC's Operating Income growth rate?
Operating Income CAGR 1Y
-67%
Over the last year, the Operating Income growth was -67%.